DESTINY-Breast03 Phase 3 Study Results

Safety Safety population n=15 Any adverse event 15 pts. (100%) Haematological adverse events Grade 1/2 Grade 3 Grade 4 Anaemia Neutropenia 46.6% 6.7% 46.6% Non-haematologic adverse events >2 patients Grade 3 15.3% Grade 4 Grade 1/2 Fatigue 66.7% Nausea 46.7% Constipation 40% Hypokalaemia 40% Diarrhoea 33.4% 6.7% Bone pain 26.6% Dyspnoea 26.6% 6.7% Fall 20% Urinary tract infection 20% 6.7% Vomiting 20% ESMO BC 2022 #165 Mini Oral AEs of special interest: ☐ Ejection fraction decrease grade 3: 1 pt., ILD grade 2 1 pt. 6 SAEs in a total of 4 patients 1 Pt. grade 5 urosepsis (not related to IMP) Daiichi-Sankyo 57

View entire presentation